(19)
(11) EP 1 218 015 A2

(12)

(88) Date of publication A3:
10.01.2002

(43) Date of publication:
03.07.2002 Bulletin 2002/27

(21) Application number: 00972695.1

(22) Date of filing: 06.10.2000
(51) International Patent Classification (IPC)7: A61K 31/70, A61K 31/445, A61K 31/195, A61P 3/00
(86) International application number:
PCT/EP0009/816
(87) International publication number:
WO 0126/639 (19.04.2001 Gazette 2001/16)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 08.10.1999 US 415307
08.10.1999 US 415308

(71) Applicants:
  • Novartis AG
    4056 Basel (CH)

    BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE CY 
  • Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
    1235 Wien (AT)

    AT 

(72) Inventors:
  • GATLIN, Marjorie, Regan
    Wilmington, DE 19806 (US)
  • BALL, Michele
    Kendall Park, NJ 08824 (US)
  • DUNNING, Beth
    Battle Creek, MI 49017 (US)

(74) Representative: Becker, Konrad et al
Novartis AG,Corporate Intellectual Property,Patent & Trademark Department
4002 Basel
4002 Basel (CH)

   


(54) PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETIC AGENT